BioLine RX Ltd（BLRX）股票分析

$1.730

-0.037 (-2.15%)收盤時

Loading chart…

最高: 1.750
開盤: 1.715
成交量加權均價: 1.73
成交量: 7.76K
市值: 45.57M
最低: 1.709
成交金額: 13.42K
企業價值/稅息折舊攤銷前利潤（TTM）: -0.45

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

www.biolinerx.com

AI 分析 of BioLine RX Ltd (BLRX)

賣出

BioLine RX Ltd is not a good buy right now due to its current price of $1.73, a very low RSI of 11.115 indicating oversold conditions, and a staggering 49.71% decline over the past year. The company also reported a widening net loss of $4.3 million in Q2 2026, which raises concerns about its financial health and sustainability.

分析師評級（4）

上檔空間 +593.64%

買進

4 買進

0 持有

0 賣出

目前: 1.73

最低

12.00

平均

12.00

最高

12.00

Jones Trading

持有

—

2025-04-02

Jones Trading

2025-04-02

目標價

—

持有

HC Wainwright & Co.

強烈買進

$26

2025-03-31

HC Wainwright & Co.

2025-03-31

目標價

$26

強烈買進

HC Wainwright & Co.

強烈買進

2024-11-25

HC Wainwright & Co.

2024-11-25

目標價

強烈買進

HC Wainwright & Co.

強烈買進

$21

2024-11-06

HC Wainwright & Co.

2024-11-06

目標價

$21

強烈買進

Jones Trading

強烈買進

2024-09-04

Jones Trading

2024-09-04

目標價

強烈買進

查看全部評級

估值指標

BioLine RX Ltd（BLRX）目前預期本益比為 93.46，5 年平均預期本益比為 15.21。

預期本益比

嚴重高估

5 年均值 P/E

15.21

目前P/E

93.46

高估

53.08

低估

-22.67

預期 EV/EBITDA

合理

5 年均值 EV/EBITDA

-1.03

目前EV/EBITDA

-0.45

高估

0.32

低估

-2.39

預期股價營收比

合理

5 年均值 P/S

14.00

目前P/S

3.96

高估

56.66

低估

-28.65

Alphio AI 對 BLRX 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%BLRX

$4.97

情境價格

基

基準

基準 · 50%BLRX

$4.62

情境價格

悲

悲觀

悲觀 · 25%BLRX

$4.26

情境價格

事件時間軸

2026-09-25 (ET)